Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $2.46 Million - $3.23 Million
-116,948 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$23.49 - $35.8 $82,402 - $125,586
-3,508 Reduced 2.91%
116,948 $3.05 Million
Q1 2021

May 14, 2021

SELL
$25.79 - $39.02 $82,682 - $125,098
-3,206 Reduced 2.59%
120,456 $4.25 Million
Q4 2020

Feb 16, 2021

SELL
$25.24 - $43.45 $487,813 - $839,758
-19,327 Reduced 13.52%
123,662 $3.12 Million
Q3 2020

Nov 13, 2020

BUY
$32.38 - $44.96 $127,868 - $177,547
3,949 Added 2.84%
142,989 $5.39 Million
Q2 2020

Aug 14, 2020

BUY
$18.39 - $54.04 $2.56 Million - $7.51 Million
139,040 New
139,040 $5.95 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Capital Bank & Trust CO Portfolio

Follow Capital Bank & Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Bank & Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Capital Bank & Trust CO with notifications on news.